- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Successful Challenges to Drug Patents
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses successes in drug patent challenges.
Transcript:
Can you share some of your success stories in challenging patents and lowering the cost of drugs for patients?
A lot of our work happened in India in the initial years on a number of first-line and second-line HIV drugs, [anti-retrovirals, ARVs]. We were successful in challenging those patents so Indian engineering companies could continue to export them to African countries. For example, India supplies 80% of generic HIV medicines to African countries, so we were able to keep that pipeline open.
In a number of cases our cases have actually lent themselves to creating leverage over the pharmaceutical companies in such that they’ve struck licensing deals. For example, we helped some of our colleagues in Ukraine and now Ukraine is included in that license as a result of that challenge.
The knock-on effect is to try and take some of the power away from the pharmaceutical companies, where you threaten the very rights that allow them to have all that power. Really, it’s about balancing the interests and making sure the system is working for both sides.
Unfortunately, I feel we’ve titled far too much in the favor of the pharmaceutical companies, and that’s why we see the problems we have today where drug prices are going up astronomically and, unfortunately, no one is able to really do anything about it. That’s why we feel our intervention is critical in terms of trying to redress some of those imbalances.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
